Currently Viewing:
Currently Reading
Quizartinib Prolongs Overall Survival in Deadly Form of AML Compared With Chemotherapy
June 19, 2018 – Laura Joszt
Gene Editing Could Reduce Toxicity of CAR T Treatment in AML
June 15, 2018 – Laura Joszt
RA Drug May Reduce Toxicity Caused By CAR T Treatment
June 14, 2018 – Samantha DiGrande
Scalp Cooling System for Chemotherapy-Induced Alopecia Approved for Multiple Solid Tumors
June 14, 2018 – Jaime Rosenberg
Link Found Between Mammographies, Other Screenings in Medicare Enrollees
June 14, 2018 – Christine Potkul
Pembrolizumab Indications Expand to Include Cervical Cancer
June 13, 2018 – Samantha DiGrande
NCI-Designated Cancer Centers Endorse Goal of Eliminating HPV-Related Cancers
June 13, 2018 – Jaime Rosenberg
Translocated Bacteria Can Lead to a Precursor Condition of Leukemia
June 12, 2018 – Laura Joszt
Outdoor Professions Carry Different Risks For Nonmelanoma Skin Cancer
June 12, 2018 – Jaime Rosenberg

Quizartinib Prolongs Overall Survival in Deadly Form of AML Compared With Chemotherapy

Laura Joszt
An investigational drug has prolonged survival in patients with a rare and deadly form of acute myeloid leukemia (AML).
An investigational drug has prolonged survival for patients with acute myeloid leukemia (AML) who have a genetic mutation called FMS-like internal tandem duplications (FLT3-ITD). The results of the phase 3 trial, which was led by The University of Texas MD Anderson Cancer Center, were presented at the European Hematology Society’s 23rd Congress.1

AML with the FLT3-ITD mutation is a rare and deadly form of the disease that affects approximately one-third of patients with AML. These patients present with more aggressive disease and are more likely to relapse after remission.2

So far, quizartinib, a second-generation FLT3 inhibitor, has shown promising activity. The new findings of the QUANTUM-R study presented at the European Hematology Society have confirmed the efficacy and safety of the treatment, as well as the value of targeting FLT3-ITD with the agent, which is a small molecule receptor tyrosine kinase inhibitor.

“Currently, there are no approved targeted therapies for patients with relapsed FLT3-ITD-associated AML, which represent a significant unmet medical need,” Jorge Cortes, MD, deputy chair and professor of Leukemia at MD Anderson, as well as the lead investigator of the QUANTUM-R study, said in a statement. “Our findings demonstrated that patients on quizartinib alone had an estimated overall survival of 27% after 52 weeks of treatment compared to 20% for patients on standard chemotherapies.”

The study enrolled adult patients who either had refractory AML or who had relapsed 6 months or less following complete remission. A total of 367 patients were randomized 2:1 to receive either quizartinib once daily or the investigator’s choice of several chemotherapy options (low-dose cytarabine; the combination of mitoxantrone, etoposide, and cytarabine; or the combination of fludarabine, cytarabine, and idarubicin).

The median overall survival was 27 weeks for patients treated with quizartinib and 20.4 weeks for patients treated with chemotherapy. Treatment-emergent adverse events were comparable between the 2 arms.

“These pivotal data confirm that targeting FLT3-IT with this potent new therapy may be of significant clinical value,” said Cortes. “These results represent the first positive phase 3 trial to demonstrate improved overall survival in patients with AML-associated FLT3-ITD.”


1. Cortes J, Khaled S, Martinelli G, et al. Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication–mutated (MUT) relapsed/refractor AML in the phase 3, randomized, controlled QUANTUM-R trial. Presented at the 23rd Congress of the European Hematology Association. June 16, 2018; Stockholm, Sweden.

2. Fathi AT, Chen YB. Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res. 2011;1(2):175-189. PMID: 22432079.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up